WHA 69, Item 16.2: Follow-up to the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination Delivered by Mario Ottiglio, Director, Public Affairs, Communications and Global Health Policy, IFPMA Thank you for the opportunity to contribute to this important discussion today. IFPMA represents leading research-based pharmaceutical companies as well as...
Read moreWHA 69, Item 11.3 Framework of engagement with non-State actors Delivered by Mario Ottiglio, Director, Public Affairs, Communications and Global Health Policy, IFPMA IFPMA welcomes continued efforts to design a framework allowing WHO to fulfill its leadership role in global health and its mandate by engaging with a varied set of actors, while managing any...
Read moreWHA 69, Item 14.4 Global action plan on antimicrobial resistance Delivered by Nina Grundmann, Associate Manager, Global Health Policy, IFPMA IFPMA commends WHO for presenting options for the establishment of a global development and stewardship framework and for its efforts to increase political awareness, engagement and leadership on AMR with the upcoming High Level Meeting...
Read moreThis blog was originally posted in Diplomatic Courier Since the start of this millennium, we have witnessed many success stories in global health. Death from infectious diseases like malaria and tuberculosis have been cut in half. A child is twice as likely to survive past their fifth birthday than he or she was fifteen year ago....
Read more‘Pharmacy-mediated substitution is defined as a framework permitting substitution of biotherapeutics at the pharmacy level without the consent of the prescribing physician. IFPMA believes there should be a distinction in public health policy between this type of substitution and the type of switching performed under medical supervision. The following policy position developed by IFPMA is...
Read morePsoriasis was recognized for the first time as a serious non-communicable disease at the World Health Assembly in 2014. To help bring the public health impact of psoriasis into focus and to help raise awareness of the range of ways that psoriasis can affect peoples’ lives, IFPMA presents the recommendations from the WHO Global report...
Read moreABPI, EFPIA and IFPMA issue joint statement following publication of the final report by the Review on AMR The Association of the British Pharmaceutical Industry (ABPI), the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) have today issued a joint statement following the publication of...
Read more